GlassScriptPhysician profile
Rajesh Rajan
NPI 1154642098
$5,790.25
in general payments reported to CMS, 2019-2025
43 companies · $910 in 2025
The $910 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $292 · 2021: $710 · 2022: $1,156 · 2023: $1,043 · 2024: $1,203 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,026 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,025.54 |
| Education | $130.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $665.61 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $619.95 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $510.40 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $497.41 | 2019-2024 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $326.22 | 2019-2024 | Rayaldee |
| Janssen Biotech, INC. | $295.78 | 2019-2025 | Stelara, Tremfya, Simponi |
| Travere Therapeutics, INC. | $261.69 | 2022-2025 | |
| Ardelyx, INC. | $230.21 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $224.50 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $220.49 | 2020-2025 | Auryxia, Vafseo |
| Abbvie INC. | $176.22 | 2021-2025 | |
| Daiichi Sankyo INC. | $155.91 | 2020-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $150.26 | 2024-2025 | |
| Novo Nordisk INC | $140.92 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $139.78 | 2019-2025 | Entyvio |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Rajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.